CD8A and neoplasm: Anti-APOC2-K70lac antibody or LDH inhibitor FX11, combined with anti-PD-1 therapy, substantially decreases Treg frequency and the proportions of TNF-α+ IFN-γ+ and CD69+ CD8+ T cells in the tumor microenvironment, conferring immunotherapeutic resistance (Chen J. et al., 2024).